VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Advances in CLL at ASH 2020: combination therapies

John Allan, MD, Weill Cornell Medicine, New York, NY, highlights the upcoming advances in the field of chronic lymphocytic leukemia (CLL) at ASH 2020. The field is now moving away from monotherapies and sequencing type approaches to optimizing how best to combine existing therapies such as Burton’s tyrosine kinase (BTK) inhibitors, venetoxclax, and anti-CD20 antibodies. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

John Allan, MD, has done consultancy work, participated in advisory boards and/or received honoraria from Pharmacyclics, Janssen, Abbvie, BeiGene, Genentech and AstraZeneca; and has received research Funding from Genentech, Janssen and TG Therapeutics.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter